For UK pharmaceutical and life sciences leaders
Regulatory complexity is slowing your pipeline before it reaches patients
Post-Brexit divergence has created duplicated submissions, longer review cycles and compliance overhead that eats directly into your development timeline, and with the cost of bringing a medicine to market running into the billions, every delay compounds.
Two minutes. Solva follows up with specific regulatory operations options.
- Increased time spent on documentation and approval processes
- Delays in product launch and market access
- Higher operational costs due to manual compliance efforts
- Difficulty in attracting and retaining regulatory talent
- Reduced speed to market for new medicines
- Diversion of R&D resources to compliance activities
- Increased operational costs due to manual compliance efforts
- Potential for significant fines from regulatory bodies for non-compliance
- Damage to company reputation due to regulatory non-compliance or product recalls
- Loss of trust among healthcare professionals and patients
The average cost of developing a new medicine is estimated to be £1.15 billion (ABPI, 2020)
Source: https://www.abpi.org.uk/media/h40bcxrq/medicine-development-process.pdf
Frequently asked questions
Why does this problem persist?
The evolving regulatory landscape, particularly post-Brexit, has introduced significant administrative burdens and complexities for UK pharmaceutical companies. This necessitates duplicated efforts for approvals and ongoing compliance, diverting resources from innovation.
What is the cost of leaving it unaddressed?
The average cost of developing a new medicine is estimated to be £1.15 billion, with a significant portion attributed to regulatory compliance and associated delays. (ABPI, 2020)
This is exactly what I do with UK private practices. Answer the few questions above and I'll come back personally with where to start. Paul.